Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CN201
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : $1,300.0 million
Deal Type : Acquisition
Merck Puts Up Potential $1.3B to Acquire Curon’s B Cell Depletion Therapy
Details : Under the terms of the agreement, Merck through a subsidiary will acquire full global rights to CN201, which is being evaluated in early-stage for treating acute lymphoblastic leukemia.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : $700.0 million
September 08, 2024
Lead Product(s) : CN201
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : $1,300.0 million
Deal Type : Acquisition
Lead Product(s) : CN201
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : $1,300.0 million
Deal Type : Acquisition
Merck Acquires Investigational B-Cell Depletion Therapy, CN201, from Curon
Details : Under the terms of the agreement, Merck through a subsidiary acquired full global rights to CN201, which is being evaluated in early-stage for treating acute lymphoblastic leukemia.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : $700.0 million
January 10, 2024
Lead Product(s) : CN201
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : $1,300.0 million
Deal Type : Acquisition
Lead Product(s) : CN202
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Novotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 31, 2021
Lead Product(s) : CN202
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Novotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CN1
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Novotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 10, 2021
Lead Product(s) : CN1
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Novotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tenalisib
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Rhizen Pharmaceuticals
Deal Size : $149.5 million
Deal Type : Licensing Agreement
Details : Curon obtains the exclusive development and commercialization rights of Tenalisib for Greater China across all oncology indications, and will lead the clinical development in that territory.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 10, 2020
Lead Product(s) : Tenalisib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Rhizen Pharmaceuticals
Deal Size : $149.5 million
Deal Type : Licensing Agreement
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 05, 2020